Symkevi is a medicine used to treat cystic fibrosis in patients aged 6 years and above. Cystic fibrosis is an inherited disease that has severe effects on the lungs, the digestive system and …

SYMDEKO是tezacaftor和ivacaftor的组合，适用于治疗6岁及以上的F508del突变纯合子或对tezacaftor / ivacaftor有反应的囊性纤维化跨膜电导调节剂（CFTR）基因中至少有一种突变的患 …

What is Symkevi and what is it used for? Symkevi is a medicine used to treat cystic fibrosis in patients aged 6 years and above. Cystic fibrosis is an inherited disease that has severe effects …

2023年6月5日 · 2018年11月2日，Vertex 制药宣布欧盟批准其新型两药复方药物 Symkevi（tezacaftor/ivacaftor），这次批准有助于该药物用于治疗更多的囊性纤维化(CF)患 …

2025年1月13日 · Symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (CF) aged 6 years and older who are homozygous for …

2018年11月5日 · PMLiVE 于 11 月 2 日报道，Vertex 制药宣布欧盟批准其新型两药复方药物 Symkevi（tezacaftor/ivacaftor），这次批准有助于该药物用于治疗更多的囊性纤维化（CF） …

Symkevi is indicated in a combination regimen with ivacaftor tablet s for the treatment of patients with cystic fibrosis (CF) aged 6 years and older who are homozygous for the F508del mutation

2020年10月29日 · The fixed-dose combination of tezacaftor / ivacaftor (trade name: Symkevi) has been approved in Germany since October 2018 for the treatment of cystic fibrosis in people …

Symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (CF) aged 6 years and older who are homozygous for the F508del mutation …

Tezacaftor with ivacaftor (Symkevi®) in combination with ivacaftor for the treatment of patients with cystic fibrosis aged 6 years and older who are homozygous for the F508del mutation or …